Skip to main content
Features
Integrations
Data
Pricing
Log In
Start Free Trial
Features
Integrations
Data
Pricing
Log In
Start Free Trial
Allen Poma
Sign up to set email alerts
24
Publications
520
Citation Statements Received
89
Citation Statements Given
How they've been cited
513
30
490
0
How they cite others
157
10
79
0
Affiliations
Tesaro (United States)
,
University of North Carolina at Chapel Hill
Publications
Order By: Most citations
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
Schwartzberg
1
,
Modiano
2
,
Rapoport
3
et al.
2015
The Lancet Oncology
152
9
190
0
Get access via publisher
Add to collection
Cite
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
Rapoport
1
,
Chasen
2
,
Gridelli
3
et al.
2015
The Lancet Oncology
144
12
171
0
Get access via publisher
Add to collection
Cite
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
Rapoport
1
,
Chua
2
,
Poma
3
et al.
2015
Support Care Cancer
Abstract
Show
67
4
80
0
Get access via publisher
Add to collection
Cite
Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist.
Poma
1
,
Christensen
2
,
Davis
3
et al.
2014
JCO
26
1
14
0
Get access via publisher
Add to collection
Cite
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
Schnadig
1
,
Modiano
2
,
Poma
3
et al.
2014
JCO
13
1
8
0
Get access via publisher
Add to collection
Cite
Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses
Carfagna
1
,
Poma
2
,
Wyrick
3
et al.
1991
Cancer Chemother. Pharmacol.
Abstract
Show
17
0
9
0
Get access via publisher
Add to collection
Cite
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
Urbán
1
,
Poma
2
,
Motta Dardeno
3
et al.
2014
JCO
8
1
5
0
Get access via publisher
Add to collection
Cite
Efficacy and safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting in subjects receiving highly emetogenic chemotherapy.
Fein
1
,
Poma
2
,
Hedley
3
2012
JCO
Abstract
Show
8
2
2
0
Get access via publisher
Add to collection
Cite
1
2
3
